This is a multicenter, phase 2, randomized trial to compare rituximab maintenance with observation after rituximab and lenalidomide (R2) induction therapy in patients with previously untreated marginal zone lymphoma. Patients who achieve complete response or partial response after R2 induction will be randomized to receive rituximab maintenance or observation.
Able to understand and voluntarily sign the informed consent form.
Age ≥18 years.
Histologically confirmed CD20-positive marginal zone lymphoma, including extranodal, splenic, or nodal subtypes.
Considered unsuitable for or unable to tolerate standard chemotherapy.
History of other malignancies that may interfere with study assessment.
Central nervous system involvement by lymphoma.
Known HIV infection or active hepatitis B/C infection.
Active or uncontrolled infection.